{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:07:19Z","timestamp":1774364839395,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.annder.2017.10.013","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T05:03:43Z","timestamp":1512536623000},"page":"182-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Herp\u00e8s chronique p\u00e9rin\u00e9al r\u00e9sistant \u00e0 l\u2019aciclovir r\u00e9v\u00e9lateur d\u2019une leuc\u00e9mie lympho\u00efde chronique"],"prefix":"10.1016","volume":"145","author":[{"given":"E.A.","family":"Casassa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Viraben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bulai Livideanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mengelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fortenfant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Konstantinou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2017.10.013_bib0145","first-page":"279","article-title":"Chronic genital ulcerations and HIV infection: 29\u00a0cases","volume":"59","author":"Gbery","year":"1999","journal-title":"Med Trop"},{"key":"10.1016\/j.annder.2017.10.013_bib0150","first-page":"967","article-title":"Perianal ulceration revealing langherans cell histiocytosis","volume":"81","author":"Landolsi","year":"2003","journal-title":"Tunis Med"},{"key":"10.1016\/j.annder.2017.10.013_bib0155","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.anuro.2006.02.002","article-title":"Buschke-Lowenstein tumour: diagnosis and treatment","volume":"40","author":"L\u00e9vy","year":"2006","journal-title":"Ann Urol"},{"key":"10.1016\/j.annder.2017.10.013_bib0160","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3315\/jdcr.2009.1032","article-title":"Acquired acrodermatitis enteropathica due to zinc deficiency in a patient with pre-existing Darier's disease","volume":"3","author":"Cheshire","year":"2009","journal-title":"J Dermatol Case Rep"},{"key":"10.1016\/j.annder.2017.10.013_bib0165","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.annder.2017.10.013_bib0170","first-page":"363","article-title":"Management of cutaneo-mucosal herpes in immunocompetent patients (ocular manifestations excluded)","volume":"31","author":"Agence nationale d\u2019accr\u00e9ditation et d\u2019\u00e9valuation en sant\u00e9","year":"2002","journal-title":"Presse Med"},{"key":"10.1016\/j.annder.2017.10.013_bib0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Minireview, resistance of herpes simplex virus to nucleoside analogues: mechanisms, prevalence and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2017.10.013_bib0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.16.1.114-128.2003","article-title":"Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy","volume":"16","author":"Bacon","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.annder.2017.10.013_bib0185","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","article-title":"Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy","volume":"28","author":"Beutner","year":"1995","journal-title":"Antiviral Res"},{"key":"10.1016\/j.annder.2017.10.013_bib0190","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1128\/AAC.39.12.2759","article-title":"Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans","volume":"39","author":"Soul-Lawton","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2017.10.013_bib0195","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.annder.2017.10.013_bib0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/asheducation-2008.1.450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","author":"Dearden","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.annder.2017.10.013_bib0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF01963751","article-title":"Persistent herpes simplex virus infection and mechanisms of virus drug resistance","volume":"8","author":"Field","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.annder.2017.10.013_bib0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1128\/AAC.21.5.744","article-title":"Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy","volume":"21","author":"Field","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2017.10.013_bib0215","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1128\/AAC.42.4.868","article-title":"Survey of resistance of herpes simplex virus to acyclovir in Northwest England","volume":"42","author":"Christophers","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2017.10.013_bib0220","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00669-10","article-title":"Genotypic characterization of UL23\u00a0thymidine kinase and UL30\u00a0DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals","volume":"54","author":"Burrel","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.annder.2017.10.013_bib0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.antiviral.2012.09.016","article-title":"Impact of novel mutations of herpes simplex virus 1\u00a0and 2\u00a0thymidine kinases on acyclovir phosphorylation activity","volume":"96","author":"Burrel","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.annder.2017.10.013_bib0230","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1086\/514229","article-title":"Chronic vulvar ulceration in an immunocompetent woman due to acyclovir resistant, thymidine kinase deficient herpes simplex virus","volume":"177","author":"Swetter","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.annder.2017.10.013_bib0235","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0140-6736(90)90101-A","article-title":"Genital and oral erosions induced by foscarnet","volume":"335","author":"Gilquin","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2017.10.013_bib0240","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/sti.2010.047431","article-title":"Topical imiquimod treatement of aciclovir\u00a0\u2013\u00a0resistant herpes simplex disease: case series and literature review","volume":"87","author":"Perkins","year":"2011","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.annder.2017.10.013_bib0245","first-page":"1015","article-title":"Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2\u00a0infection","volume":"137","author":"Gilbert","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2017.10.013_bib0250","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/cid\/cit592","article-title":"Recalcitrant pseudotumoral anogenitalherpes simplex virus type 2\u00a0in HIV-infected patients: effective therapeutic strategy","volume":"57","author":"Sbidian","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2017.10.013_bib0255","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1073\/pnas.86.12.4736","article-title":"Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate","volume":"86","author":"Coen","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.annder.2017.10.013_bib0260","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1086\/517513","article-title":"Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals","volume":"44","author":"Holmes","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.annder.2017.10.013_bib0265","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1099\/0022-1317-70-4-869","article-title":"The role of herpes simplex virus type 1\u00a0thymidine kinase in pathogenesis","volume":"70","author":"Efstathiou","year":"1989","journal-title":"J Gen Virol"},{"key":"10.1016\/j.annder.2017.10.013_bib0270","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1128\/jvi.67.11.6903-6908.1993","article-title":"Herpes simplex virus thymidine kinase and specific stages of latency in murine trigeminal ganglia","volume":"67","author":"Jacobson","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.annder.2017.10.013_bib0275","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1128\/jvi.61.7.2171-2174.1987","article-title":"Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation","volume":"61","author":"Tenser","year":"1987","journal-title":"J Virol"},{"key":"10.1016\/j.annder.2017.10.013_bib0140","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/infdis\/jis237","article-title":"Latent acyclovir\u00a0\u2013\u00a0resistant herpes simplex virus type 1\u00a0in trigeminal ganglia of immunocompetent individuals","volume":"205","author":"Van Velzen","year":"2012","journal-title":"J Infect Dis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817310219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817310219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:05:53Z","timestamp":1758971153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963817310219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0151963817310219"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2017.10.013","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herp\u00e8s chronique p\u00e9rin\u00e9al r\u00e9sistant \u00e0 l\u2019aciclovir r\u00e9v\u00e9lateur d\u2019une leuc\u00e9mie lympho\u00efde chronique","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}